Johnson & Johnson (NYS:JNJ) will pay $2.2 billion (1.3
billion pounds) to the U.S. government to end civil and criminal investigations
into kickbacks to pharmacists and the marketing of pharmaceuticals for
off-label uses, a person familiar with the settlement said on Monday.
The settlement with the company and its subsidiaries covers
the marketing of schizophrenia treatment Risperdal and of heart drug Natrecor,
said the source, who spoke on condition of anonymity.
Risperdal is sold by J&J unit Janssen Pharmaceuticals
Inc, which is expected to plead guilty to misdemeanor allegations of
misbranding, the source said.J&J disclosed in a securities filing in 2011
it had reached an agreement to resolve criminal penalties related to the
promotion of Risperdal, a one-time big-selling product for the company, but
that certain issues remained open. Read more.
No comments:
Post a Comment